Immunotherapies

Question 1

Ipilimumab(Yervoy®)

Answer 1

Ipilimumab(Yervoy®)

• Mechanism of action: blocks the Cytotoxic T-Cell Lymphocyte associated Antigen (CTLA-4) inhibitory signal, and allows the CTLs to destroy the cancer cells
• Indicated for treatment of melanoma
• Side effects are immunological-related: rash, diarrhea, thyroid

Question 2

Anti-Programmed Cell Death-1 (PD-1)

Answer 2

Anti-Programmed Cell Death-1 (PD-1)
- PD-1 (Programmed Cell Death) is an inhibitory signaling receptor expressed on activated T cells, enhance the ability of T cells to kill tumor

Drugs:

• Pembrolizumab(Keytruda®), Nivolumab(Opdivo®) –PD-1 inhibitor
• Atezolizumab(Tecentriq®), Avelumab(Bavencio®) –PD-L1 inhibitor

Question 3

Pembrolizumab(Keytruda®),

Answer 3

PD-1 inhibitor

Question 4

Nivolumab(Opdivo®) –

Answer 4

PD-1 inhibitor

Question 5

Atezolizumab(Tecentriq®),

Answer 5

PD-L1 inhibitor

Question 6

Avelumab(Bavencio®) –

Answer 6

PD-L1 inhibitor

Question 7

Immune-related adverse event for immunotherapy

Answer 7

Immune-related adverse event for immunotherapy

• Colitis
• Hypophysitis
• Arthritis
• Dermatitis
• Adrenal insufficiency
• Rash
• Hepatitis
• Motor and sensory neuropathies
• Pneumonitis 
• Thyroiditis
• Pancreatitis